Retrophin (NASDAQ:RTRX) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Saturday, December 30th.
RTRX has been the topic of a number of other research reports. Zacks Investment Research cut Retrophin from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 14th. ValuEngine cut Retrophin from a “hold” rating to a “sell” rating in a research report on Monday, November 20th. Finally, BMO Capital Markets restated a “buy” rating and issued a $44.00 price target on shares of Retrophin in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. Retrophin presently has an average rating of “Hold” and an average price target of $44.00.
Retrophin (NASDAQ RTRX) opened at $24.70 on Friday. The company has a market capitalization of $972.84, a price-to-earnings ratio of -16.36 and a beta of 0.96. Retrophin has a 52-week low of $15.55 and a 52-week high of $26.44. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.83 and a current ratio of 3.88.
Retrophin (NASDAQ:RTRX) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.21). Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The company had revenue of $40.34 million during the quarter, compared to analysts’ expectations of $40.51 million. During the same quarter last year, the business posted ($0.09) earnings per share. The company’s revenue for the quarter was up 18.8% on a year-over-year basis. equities research analysts predict that Retrophin will post -1.25 EPS for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC boosted its stake in shares of Retrophin by 1.8% during the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock worth $158,000 after acquiring an additional 146 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Retrophin by 1.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 30,520 shares of the biopharmaceutical company’s stock valued at $592,000 after buying an additional 290 shares in the last quarter. Legal & General Group Plc lifted its stake in Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 355 shares in the last quarter. AJO LP lifted its stake in Retrophin by 1.9% in the 2nd quarter. AJO LP now owns 59,681 shares of the biopharmaceutical company’s stock valued at $1,157,000 after buying an additional 1,094 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its stake in Retrophin by 3.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,471 shares of the biopharmaceutical company’s stock valued at $649,000 after buying an additional 1,200 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/01/14/retrophin-rtrx-lowered-to-hold-at-bidaskclub-updated-updated.html.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.